Dr. Harry Glen, MD is a distinguished ophthalmologist and the first principal investigator to perform the groundbreaking Opti-K™ procedure as part of the U.S. FDA clinical trial. He has presented his findings at prestigious international symposia and published his work in respected medical journals. As a comprehensive general ophthalmologist in active clinical practice, Dr. Glen has consistently advocated for minimally and non-invasive technologies to reduce complications, side effects, discomfort, and recovery times—an approach that naturally aligned with his dedication to advancing the Opti-K™ procedure.
Dr. Glen earned his Bachelor of Arts degree in Biology with honors from Franklin and Marshall College in Lancaster, Pennsylvania, before pursuing further education at Harvard University in Cambridge, Massachusetts. He completed his medical degree at Wake Forest University School of Medicine in Winston-Salem, North Carolina, where he also undertook externships in dermatology at the Warren Alpert Medical School of Brown University and ophthalmology at Harvard Medical School’s Massachusetts Eye and Ear Infirmary. Dr. Glen further refined his expertise through a flexible medical internship at New Hanover Hospital in Wilmington, North Carolina.
A graduate of Georgetown University’s Center for Sight, Dr. Glen is Board Certified by the American Board of Ophthalmology and is an active Fellow of the American Academy of Ophthalmology. His dedication to advancing ophthalmic care and commitment to innovation continue to position him as a leader in the field, shaping the future of vision care through pioneering technologies like Opti-K™.
